Premium
Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration‐resistant prostate cancer in men
Author(s) -
Hakariya Tomoaki,
Shida Yohei,
Tsurusaki Toshifumi,
Watanabe Junichi,
Furukawa Masataka,
Matsuya Fukuzo,
Miyata Yasuyoshi,
Sakai Hideki
Publication year - 2018
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.13542
Subject(s) - enzalutamide , ethinylestradiol , medicine , prostate cancer , docetaxel , urology , oncology , prostate specific antigen , cancer , population , androgen receptor , environmental health , research methodology
Objective To elucidate the effect of prior use of ethinylestradiol on enzalutamide treatment for men with castration‐resistant prostate cancer. Methods We retrospectively analyzed data from 99 consecutive patients (median age 72 years, range 50–88 years) treated with enzalutamide for castration‐resistant prostate cancer between May 2014 and November 2015 after receiving several lines of hormonal therapy. Results A total of 45 patients were given ethinylestradiol before enzalutamide. The prostate‐specific antigen response rate (decline in prostate‐specific antigen >50% from baseline) of patients receiving ethinylestradiol and enzalutamide were 51.1% and 41.4%, respectively. Cross‐resistance between ethinylestradiol and enzalutamide was clearly observed in the setting of pre‐docetaxel. In multivariate analysis, the T stage and number of therapies before enzalutamide were the only significant predictors of prostate‐specific antigen response to enzalutamide. However, in patients treated pre‐docetaxel use, prior use of ethinylestradiol was a significant predictor of prostate‐specific antigen response to enzalutamide, whereas ethinylestradiol did not affect the overall survival of these patients. Conclusions Cross‐resistance between ethinylestradiol and enzalutamide in the setting of pre‐docetaxel therapy seems to be evident. Therefore, ethinylestradiol should be used prudently before enzalutamide in this setting.